Bruker Corporation. (1/7/25). "Press Release: Bruker Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Billerica, MA.

	Organisation	Bruker Corporation (Nasdaq: BRKR)
	Group	Bruker (Group)
	Organisation 2	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco
	Product 2	analytical instrument
	Index term	Bruker–JPMorgan Chase: investor conference, 202401 supply service Bruker presents at JP Morgan Healthcare Conference 2024
	Person	Laukien, Frank H. (Bruker 201204 President + CEO)
	Person 2	Munch, Mark R. (Bruker Corp 201407 President Bruker MAT Group before President Bruker Nano Surfaces Business)

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 8th, 2024 at 8:15 AM Pacific Standard Time.

A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Record changed: 2025-01-20